An Open Label Compassionate Use Trial of Ublituximab and/or Umbralisib (TGR-1202) in Combination with other Novel Agents or as Single Agents in Subjects Currently Receiving Treatment on a TG Therapeutics Study.
Categories (click each to see list of all clinical trials associated with that category): Lymphoma/Chronic lymphocytic leukemia (CLL)
Current Status: Open to accrual
Phase: IV
Principal Investigator: Lunning, Matthew
Contact Information:
Susan Blumel, RN
402-559-9183
sblumel@unmc.edu
Eligibility: https://clinicaltrials.gov/ct2/show/NCT03207256#eligibility
Summary
This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or as single agents in patients currently receiving treatment on Ublituximab and/or TGR-1202 trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.